BioWorld Asia

April 6, 2005

PharmaMar's Yondelis Phase III Trial Started In Ovarian Cancer

Taking aim at relapsed ovarian cancer patients considered incurable, Madrid, Spain-based PharmaMar SA is starting a Phase III trial with Yondelis (trabectedin), a compound first isolated from marine tunicates. (BioWorld International) Read More

Rosetta Genomics Brings In $4M For Preclinical Studies

Identifying Pre-Eclampsia Gene Could Bring Diagnostic Testing

Nautilus Biotech Gets EUR7.25M In Third Round Of Financing

Ark, Boehringer Ingelheim Form Collaboration Over IP

Syngenta Slip-Up Causes Red Faces Across European Union

Israeli Chief Scientist Designates Biotech, Nanotech High Priorities

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...